Cargando…

High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study

OBJECTIVES: Tumor mutation burden (TMB) is an emerging predictive cancer biomarker. Few studies have addressed the prognostic role of TMB in non-small cell lung carcinoma, with conflicting results. Moreover, the association of TMB with different histological subtypes of lung adenocarcinoma has hithe...

Descripción completa

Detalles Bibliográficos
Autores principales: Talvitie, Eva-Maria, Vilhonen, Heikki, Kurki, Samu, Karlsson, Antti, Orte, Katri, Almangush, Alhadi, Mohamed, Hesham, Liljeroos, Lassi, Singh, Yajuvinder, Leivo, Ilmo, Laitinen, Tarja, Kallajoki, Markku, Taimen, Pekka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317687/
https://www.ncbi.nlm.nih.gov/pubmed/32585428
http://dx.doi.org/10.1016/j.neo.2020.05.004
_version_ 1783550682577502208
author Talvitie, Eva-Maria
Vilhonen, Heikki
Kurki, Samu
Karlsson, Antti
Orte, Katri
Almangush, Alhadi
Mohamed, Hesham
Liljeroos, Lassi
Singh, Yajuvinder
Leivo, Ilmo
Laitinen, Tarja
Kallajoki, Markku
Taimen, Pekka
author_facet Talvitie, Eva-Maria
Vilhonen, Heikki
Kurki, Samu
Karlsson, Antti
Orte, Katri
Almangush, Alhadi
Mohamed, Hesham
Liljeroos, Lassi
Singh, Yajuvinder
Leivo, Ilmo
Laitinen, Tarja
Kallajoki, Markku
Taimen, Pekka
author_sort Talvitie, Eva-Maria
collection PubMed
description OBJECTIVES: Tumor mutation burden (TMB) is an emerging predictive cancer biomarker. Few studies have addressed the prognostic role of TMB in non-small cell lung carcinoma, with conflicting results. Moreover, the association of TMB with different histological subtypes of lung adenocarcinoma has hitherto not been systematically evaluated. Here we studied the prognostic value of TMB and its distribution in different histological subtypes of lung adenocarcinomas in a retrospective cohort using the most recent updated classification guidelines. MATERIALS AND METHODS: 176 surgically resected stage I–IV lung adenocarcinomas were histologically reclassified according to WHO 2015 guidelines. A modified classification subdividing the acinar subtype into classic acinar, complex glandular and cribriform subtypes was further applied and potentially prognostic histopathological characteristics such as tumor-infiltrating lymphocytes were evaluated. 148 patients with stage I–III tumors and complete follow-up data were included in the survival analyses. TMB was determined by a commercial next generation sequencing panel from 131 tumors, out of which 105 had survival data available. RESULTS: Predominant micropapillary, solid and complex glandular as well as nonpredominant cribriform histological subtypes were associated with significantly shorter survival. High TMB concentrated in micropapillary, solid and acinar predominant subtypes. Interestingly, TMB ≥ 14 mutations/MB conferred a stage- and histology-independent survival benefit compared to TMB < 14 in multivariable analysis for overall (HR 0.284, 95% CI 0.14–0.59, P=0.001) and disease-specific survival (HR 0.213, 95% CI 0.08–0.56, P=0.002). CONCLUSION: TMB was an independent biomarker of favorable prognosis in our cohort of lung adenocarcinoma despite being associated with predominant histological subtypes considered aggressive.
format Online
Article
Text
id pubmed-7317687
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-73176872020-07-06 High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study Talvitie, Eva-Maria Vilhonen, Heikki Kurki, Samu Karlsson, Antti Orte, Katri Almangush, Alhadi Mohamed, Hesham Liljeroos, Lassi Singh, Yajuvinder Leivo, Ilmo Laitinen, Tarja Kallajoki, Markku Taimen, Pekka Neoplasia Original article OBJECTIVES: Tumor mutation burden (TMB) is an emerging predictive cancer biomarker. Few studies have addressed the prognostic role of TMB in non-small cell lung carcinoma, with conflicting results. Moreover, the association of TMB with different histological subtypes of lung adenocarcinoma has hitherto not been systematically evaluated. Here we studied the prognostic value of TMB and its distribution in different histological subtypes of lung adenocarcinomas in a retrospective cohort using the most recent updated classification guidelines. MATERIALS AND METHODS: 176 surgically resected stage I–IV lung adenocarcinomas were histologically reclassified according to WHO 2015 guidelines. A modified classification subdividing the acinar subtype into classic acinar, complex glandular and cribriform subtypes was further applied and potentially prognostic histopathological characteristics such as tumor-infiltrating lymphocytes were evaluated. 148 patients with stage I–III tumors and complete follow-up data were included in the survival analyses. TMB was determined by a commercial next generation sequencing panel from 131 tumors, out of which 105 had survival data available. RESULTS: Predominant micropapillary, solid and complex glandular as well as nonpredominant cribriform histological subtypes were associated with significantly shorter survival. High TMB concentrated in micropapillary, solid and acinar predominant subtypes. Interestingly, TMB ≥ 14 mutations/MB conferred a stage- and histology-independent survival benefit compared to TMB < 14 in multivariable analysis for overall (HR 0.284, 95% CI 0.14–0.59, P=0.001) and disease-specific survival (HR 0.213, 95% CI 0.08–0.56, P=0.002). CONCLUSION: TMB was an independent biomarker of favorable prognosis in our cohort of lung adenocarcinoma despite being associated with predominant histological subtypes considered aggressive. Neoplasia Press 2020-06-22 /pmc/articles/PMC7317687/ /pubmed/32585428 http://dx.doi.org/10.1016/j.neo.2020.05.004 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Talvitie, Eva-Maria
Vilhonen, Heikki
Kurki, Samu
Karlsson, Antti
Orte, Katri
Almangush, Alhadi
Mohamed, Hesham
Liljeroos, Lassi
Singh, Yajuvinder
Leivo, Ilmo
Laitinen, Tarja
Kallajoki, Markku
Taimen, Pekka
High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
title High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
title_full High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
title_fullStr High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
title_full_unstemmed High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
title_short High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
title_sort high tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: a population-based single-institution study
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317687/
https://www.ncbi.nlm.nih.gov/pubmed/32585428
http://dx.doi.org/10.1016/j.neo.2020.05.004
work_keys_str_mv AT talvitieevamaria hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT vilhonenheikki hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT kurkisamu hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT karlssonantti hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT ortekatri hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT almangushalhadi hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT mohamedhesham hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT liljerooslassi hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT singhyajuvinder hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT leivoilmo hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT laitinentarja hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT kallajokimarkku hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy
AT taimenpekka hightumormutationburdenpredictsfavorableoutcomeamongpatientswithaggressivehistologicalsubtypesoflungadenocarcinomaapopulationbasedsingleinstitutionstudy